The eosinophil count is a component of a complete blood count (CBC) that serves as a valuable indicator of immune system function and overall health.
Eosinophils, a type of white blood cell, play a crucial role in the body's response to allergens, parasites, and certain infections. Understanding the significance of eosinophil count can provide valuable insights into various medical conditions, ranging from allergies and asthma to autoimmune diseases and parasitic infections.
This article explores the clinical applications of eosinophil count, covering its definition, testing procedure, interpretation, and implications for health. By delving into the factors influencing eosinophil count and strategies for managing abnormal results, this resource offers comprehensive insights into the role of eosinophils in health assessment and disease diagnosis.
Eosinophil count refers to the measurement of the number of eosinophils, a type of white blood cell, present in a person's bloodstream. Eosinophils play a crucial role in the immune system's response to allergens, parasites, and certain infections.
Eosinophils are a type of white blood cell named granulocytes, so called because they contain granules. The granules contain a variety of chemicals that, when released, stimulate an immune response.
Eosinophils are particularly important in combating parasitic infections and modulating allergic reactions through the release of cytokines and cytotoxic granules.
Eosinophils primarily localize within the tissues of the respiratory and gastrointestinal tracts. They have a lifespan of approximately 8 to 12 days.
In healthy individuals eosinophils constitute less than 5% of circulating leukocytes. Fluctuations in their numbers can indicate underlying health conditions.
Several factors can influence eosinophil count including allergic reactions, parasitic infections, autoimmune disorders, medications, and environmental exposures.
Allergies, asthma, and parasitic infections commonly lead to elevated eosinophil counts, as the body responds to these triggers by releasing eosinophils to combat the perceived threat.
In some individuals, certain cancers or genetic alterations may cause high eosinophil counts.
Eosinophils are produced in response to elevations in IL-5, so many pharmaceutical agents target IL-5 production to reduce eosinophil levels.
Conversely, factors such as extreme stress, corticosteroid use, acute infections, certain endocrine disorders and certain medications may decrease eosinophil counts. [14.]
Eosinophil count is run as part of a complete blood count or CBC, which is considered routine blood work.
Collecting a blood sample for eosinophil count typically involves venipuncture, where a healthcare professional draws blood from a vein, usually in the arm. The collected blood sample is then transferred into a specialized tube containing an anticoagulant to prevent clotting.
Preparing for an eosinophil count test typically does not require any special preparations. However, it's essential to inform the healthcare provider about any medications or supplements being taken, as certain drugs may affect eosinophil levels.
Additionally, it's crucial to follow any specific instructions provided by the healthcare provider regarding fasting or medication restrictions before the test. It's also essential to ensure that the blood sample is collected correctly to obtain accurate results.
The normal range for eosinophil count may vary among labs, but the typical reference range is
Eosinophil blood count (absolute): 50-500/mm^3 [8.]
A count within the normal range generally suggests that the immune system is functioning adequately, while elevated or decreased counts may indicate underlying health issues that require further investigation.
High eosinophil count is also known as eosinophilia, and is further characterized as primary or secondary.
Primary Eosinophilia
Primary eosinophilia refers to a condition where an increased level of eosinophils in the blood or tissues occurs without an identifiable underlying cause. This type of eosinophilia is characterized by eosinophilic proliferation as a primary disorder, often involving abnormal regulation of eosinophil production or survival.
These conditions result from intrinsic abnormalities in the bone marrow or immune system, leading to sustained elevation of eosinophil counts.
Secondary Eosinophilia
Secondary eosinophilia refers to an elevated level of eosinophils in the blood or tissues resulting from an underlying cause or condition rather than a primary disorder of eosinophil production or regulation.
Secondary eosinophilia is a reactive response to external factors or underlying diseases, leading to an increase in eosinophil counts beyond normal levels.
Degree of Eosinophilia
Eosinophilia is further characterized according to the number of eosinophils present:
The hypereosinophilic syndrome is characterized by an absolute eosinophil count exceeding 1500/mm^3 observed on at least two occasions spaced one month apart or significant tissue eosinophilia.
Primary Causes of Eosinophilia
Secondary Causes of Eosinophilia
Common symptoms of eosinophilia vary depending on the underlying cause and the severity of the condition.
In mild cases, individuals may be asymptomatic or experience nonspecific symptoms such as fatigue, weakness, or malaise. However, in more severe cases, eosinophilia may manifest with symptoms related to organ system involvement.
Respiratory symptoms such as coughing, wheezing, shortness of breath, or asthma exacerbations may occur if eosinophils infiltrate the lungs.
Gastrointestinal symptoms such as abdominal pain, diarrhea, nausea, or vomiting may occur if eosinophils accumulate in the gastrointestinal tract.
Skin manifestations such as rash, hives, or pruritus may also be present, particularly in allergic or hypersensitivity reactions.
Systemic symptoms such as fever, weight loss, or night sweats may occur in cases of underlying systemic diseases associated with eosinophilia.
Low eosinophil count is also known as eosinopenia.
Eosinopenia is primarily observed as a secondary phenomenon, with primary or constitutional eosinopenia being extremely rare and reported only in a few cases, some of which also involve a decrease in basophils.
When evaluating a patient with eosinopenia, a thorough investigation of potential secondary causes including medications and underlying medical conditions is essential before considering constitutional factors.
In cases where no external cause of eosinopenia is identified, a bone marrow aspirate and biopsy may be necessary, along with comprehensive genetic testing to identify variants associated with eosinophil maturation, proliferation, and activation. [11.]
Eosinopenia is overwhelmingly a secondary manifestation of a primary condition or medication use.
Common symptoms associated with eosinopenia can vary widely depending on the underlying cause.
In many cases, eosinopenia is a secondary phenomenon observed during acute stress responses, such as surgery, trauma, or severe bacterial infections. Therefore, symptoms may primarily reflect the underlying condition rather than eosinopenia itself.
However, if eosinopenia persists or is associated with chronic inflammatory diseases or immunodeficiency disorders, symptoms may include recurrent infections, fatigue, weakness, and generalized malaise.
Additionally, eosinopenia secondary to medication use or allergic reactions may present with symptoms related to the medication's side effects or the allergic response, such as skin rash, respiratory distress, or gastrointestinal disturbances.
Eosinopenia does not always cause symptoms or hold clinical relevance, as the immune system can compensate for a lack of eosinophils.
Identify and treat underlying causes: addressing the underlying condition or trigger of eosinophilia, such as allergies, infections, or autoimmune disorders, is essential for reducing eosinophil levels.
Avoid allergens: minimizing exposure to known airborne or digestive allergens or triggers can help prevent eosinophil activation and accumulation.
Dietary modifications: in cases of eosinophilic gastrointestinal disorders, dietary changes such as eliminating certain foods or allergens may help reduce eosinophilic inflammation.
Lifestyle modifications: employ stress management strategies to help regulate the immune system and reduce eosinophil activation. [13.]
Corticosteroids: oral or inhaled corticosteroids may be prescribed to suppress the immune system and reduce inflammation associated with eosinophilia.
Immunomodulators: drugs such as methotrexate or cyclosporine may be used to modulate the immune response and reduce eosinophil production. [7.]
Biologic therapies: monoclonal antibodies such as mepolizumab or benralizumab may be prescribed to target specific proteins involved in eosinophil production and function. [9.]
Anti-parasitic medications: in cases of eosinophilia due to parasitic infections, medications such as albendazole or ivermectin may be used to eliminate the parasites. [10.]
Treatment of underlying conditions: addressing the underlying cause of eosinopenia such as infections, inflammatory conditions, or medications, is crucial for restoring normal eosinophil levels.
Medication adjustments: if medications are responsible for causing eosinopenia, adjusting or discontinuing the offending drugs may help normalize eosinophil counts.
Immune-modulating therapies: in cases of primary eosinopenia or severe immune suppression, immune-modulating therapies such as granulocyte colony-stimulating factor (G-CSF) may be used to stimulate eosinophil production and function. [1., 3.]
Click here to review testing options and order a CBC to assess eosinophil count.
[1.] Håkansson L, Höglund M, Jönsson UB, Torsteinsdottir I, Xu X, Venge P. Effects of in vivo administration of G-CSF on neutrophil and eosinophil adhesion. Br J Haematol. 1997 Sep;98(3):603-11. doi: 10.1046/j.1365-2141.1997.2723093.x. PMID: 9332315.
[2.] Kanuru S, Sapra A. Eosinophilia. [Updated 2023 Jun 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560929/
[3.] Karawajczyk M, Höglund M, Ericsson J, Venge P. Administration of G-CSF to healthy subjects: the effects on eosinophil counts and mobilization of eosinophil granule proteins. Br J Haematol. 1997 Feb;96(2):259-65. doi: 10.1046/j.1365-2141.1997.d01-2045.x. PMID: 9029010.
[4.] Klion AD. Eosinophilia: a pragmatic approach to diagnosis and treatment. Hematology Am Soc Hematol Educ Program. 2015;2015:92-7. doi: 10.1182/asheducation-2015.1.92. PMID: 26637706.
[5.] Kolkhir P, Church MK, Altrichter S, Skov PS, Hawro T, Frischbutter S, Metz M, Maurer M. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment. J Allergy Clin Immunol Pract. 2020 Jan;8(1):318-325.e5. doi: 10.1016/j.jaip.2019.08.025. Epub 2019 Aug 28. PMID: 31472293.
[6.] Larsen RL, Savage NM. How I investigate Eosinophilia. Int J Lab Hematol. 2019 Apr;41(2):153-161. doi: 10.1111/ijlh.12955. Epub 2018 Nov 30. PMID: 30499630.
[7.] Nguyen E, Yanes D, Imadojemu S, Kroshinsky D. Evaluation of Cyclosporine for the Treatment of DRESS Syndrome. JAMA Dermatology. 2020;156(6):704. doi:https://doi.org/10.1001/jamadermatol.2020.0048
[8.] Pagana KD, Pagana TJ, Pagana TN. Mosby’s Diagnostic and Laboratory Test Reference. 14th ed. St. Louis, MO: Elsevier; 2019. 974.
[9.] Pitlick MM, Li JT, Pongdee T. Current and emerging biologic therapies targeting eosinophilic disorders. World Allergy Organ J. 2022 Jul 31;15(8):100676. doi: 10.1016/j.waojou.2022.100676. PMID: 35983569; PMCID: PMC9356173.
[10.] Vaisben E, Brand R, Kadakh A, Nassar F. The role of empirical albendazole treatment in idiopathic hypereosinophilia - a case series. Can J Infect Dis Med Microbiol. 2015 Nov-Dec;26(6):323-4. doi: 10.1155/2015/531675. PMID: 26744590; PMCID: PMC4692302.
[11.] Walkovich K, Connelly JA. Disorders of white blood cells. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. Published online 2022:207-235. doi:https://doi.org/10.1016/b978-0-12-821671-2.00002-7
[12.] Xia Z. Eosinopenia as an early diagnostic marker of COVID-19 at the time of the epidemic. EClinicalMedicine. 2020 Jun 18;23:100398. doi: 10.1016/j.eclinm.2020.100398. PMID: 32572392; PMCID: PMC7299848.
[13.] Zheng PY, Feng BS, Oluwole C, Struiksma S, Chen X, Li P, Tang SG, Yang PC. Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine. Gut. 2009 Nov;58(11):1473-9. doi: 10.1136/gut.2009.181701. Epub 2009 Aug 2. PMID: 19651632.
[14.] Zini G. Abnormalities in leukocyte morphology and number. Blood and Bone Marrow Pathology. Published online 2011:247-261. doi:https://doi.org/10.1016/b978-0-7020-3147-2.00016-x